Skip to content

Thursday, November 21, 2024

Latest:

FROM THE LABS: From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide
The dangers of vaping
Thanksgiving nutrition: enjoying holiday favorites while staying on track with your health goals
How tau becomes a ‘bad guy’ that contributes to Alzheimer’s disease
Diabetes and depression: Is there a connection between them?

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

PCSK9 inhibitor

Clinical trial finds that oral drug MK-0616 substantially reduces ‘bad’ cholesterol

March 14, 2023 atherosclerosis, bad cholesterol, Cardiovascular Disease, LDL-cholesterol, MK-0616, PCSK9 inhibitor, Research

MK-016 could offer another potential option to achieve guideline-recommended LDL-C levels resulting in reduction of cardiovascular risk.

From the Labs: Image of the Month

From the Labs: Aging signs.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951